H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) dropped 49.5% during mid-day trading on Wednesday . The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares changed hands during mid-day trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Performance
The company has a 50-day moving average of $2.02 and a 200-day moving average of $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than H-CYTE
- How to Use the MarketBeat Dividend Calculator
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- How Do Stock Buybacks Affect Shareholders?
- 3 Stocks to Consider Buying in October
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
